Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive. Patients with advanced ...

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

Patients with advanced bladder cancer treated with an immunosuppressant drug were a third less likely to see the disease ...

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer. Now, new data suggests new ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...